The ADDF seeks to support studies of cognitive symptoms due to health conditions, comparative effectiveness research, and epidemiological studies that probe whether the use or choice of drugs alters the risk for dementia or cognitive decline.
The Prevention Pipeline RFP supports:
- Studies of Cognitive Decone and Risk Reduction
- Comparative Effectiveness Research
- Studies Leveraging the Consoritum of Cohorts for Alzheimer's Prevention Action (CAPA)
Drug mechanisms or modes of action: Novel drug mechanisms and modes of action related to the biology of aging and other emerging therapeutic areas for dementia are considered high priority. These include, but are not limited to:
- Mitochondrial & metabolic function
- Synaptic activity and neurotransmitters
- Vascular function
- Other mechanisms and modes of action related to the biology of aging (e.g. senescent cells)
- Other novel mechanisms or modes of action that are supported by compelling evidence demonstrating a rational biological connection to the disease process
- Please note: Anti-amyloid approaches (e.g., anti-amyloid aggregation, beta-amyloid vaccines, beta- or gamma-secretase inhibitors) and cholinesterase inhibitor proposals will not be considered
Funding is open to researchers and clinicians worldwide at:
- Academic medical centers and universities or nonprofits. Industry partnerships are encouraged.
- Biotechnology companies. Existing companies and new startups are both eligible.
- NOTE: Funding is provided through mission-related investments that require return on investment based upon scientific and/or business milestones (see Our Research Strategy for more information).
Letter of Intent:
February 4, 2022
May 20, 2022
September 30, 2022
April 8, 2022
July 22, 2022
December 2, 2022